- Home
- CPHC vs IBIO Comparison
CPHC vs IBIO Comparison
Compare CPHC & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPHC | IBIO |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.1M | 84.0M |
| IPO Year | 2016 | 2009 |
Fundamental Metrics
Financial Performance| Metric | CPHC | IBIO |
|---|---|---|
| Price | $16.84 | $1.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | 1.6K | ★ 777.5K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | ★ 73.08 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $59,227,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $523.00 | ★ N/A |
| Revenue Growth | ★ 0.14 | N/A |
| 52 Week Low | $14.49 | $0.56 |
| 52 Week High | $21.61 | $3.82 |
Technical Indicators
Market Signals| Indicator | CPHC | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 47.34 |
| Support Level | $16.03 | $1.43 |
| Resistance Level | $17.42 | $1.80 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 74.99 | 45.68 |
Price Performance
Historical ComparisonAbout CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the real estate development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.